🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BI 207127

Found 21 matching trials

Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel

PHASE1

Investigate the effect of multiple oral doses of BI 207127 + faldaprevir (F...

Status

Terminated

Location

1241.31.2 Boehringer Ingelheim Investigational Site

Start Date

2013-11

Trial ID

NCT01941615

Treatments Being Tested

faldaprevir Microgynon®BI 207127

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

PHASE2

The objective of this trial is to investigate tolerability, safety, pharmac...

Status

Completed

Location

1241.25.002 Boehringer Ingelheim Investigational Site

Start Date

2012-02

Trial ID

NCT01528735

Treatments Being Tested

BI 207127 NA peginterferon Ribavirin Ribavirin BI 207127 NA BI 201335 NA BI 201335 NA peginterferon

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

PHASE1

The purpose of this study was to investigate antiviral activity, safety and...

Status

Completed

Location

Multiple Locations

Start Date

2007-12

Trial ID

NCT02176525

Treatments Being Tested

BI 207127 NA Placebo

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

PHASE3

The aim of this trial is to evaluate efficacy and safety of treatment with ...

Status

Withdrawn

Location

1241.37.61002 Boehringer Ingelheim Investigational Site

Start Date

2013-05

Trial ID

NCT01858961

Treatments Being Tested

BI 201335 ribavirin BI 207127 Telaprevir ribavirin Pegylated Interferon

Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

PHASE1

The purpose of this trial is to investigate the effect of food with differe...

Status

Terminated

Location

1241.44.49001 Boehringer Ingelheim Investigational Site

Start Date

2013-11

Trial ID

NCT01983566

Treatments Being Tested

BI 207127 high fat BI 207127 with Omeprazole BI 207127 BI 207127 low fat

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

PHASE2

To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120...

Status

Completed

Location

1241.30.10003 Boehringer Ingelheim Investigational Site

Start Date

2013-04

Trial ID

NCT01830127

Treatments Being Tested

Ribavirin BI 207127 high dose Faldaprevir Ribavirin BI 207127 low dose Faldaprevir

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

PHASE3

The aim of the study is to confirm efficacy of treatment for 16 and 24 week...

Status

Completed

Location

1241.20.00026 Boehringer Ingelheim Investigational Site

Start Date

2012-12

Trial ID

NCT01732796

Treatments Being Tested

Ribavirin (RBV)BI 201335 (Faldaprevir)Ribavirin (RBV)BI 207127 BI 201335 (Faldaprevir)Ribavirin (RBV)BI 207127 Faldaprevir (BI 201335)BI 207127

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

PHASE1

Phase 1 study to assess the pharmacokinetics and routes of elimination of a...

Status

Completed

Location

1241.22.001 Boehringer Ingelheim Investigational Site

Start Date

2012-05

Trial ID

NCT01605461

Treatments Being Tested

BI 207127 NA

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

PHASE1

The objective of this study is to evaluate the effect of multiple doses of ...

Status

Completed

Location

1241.40.1 Boehringer Ingelheim Investigational Site

Start Date

2013-10

Trial ID

NCT01965431

Treatments Being Tested

BI 207127 BI 207127 placebo Faldaprevir placebo Faldaprevir Moxifloxacin (Avalox®)

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

PHASE1

Study to investigate the relative bioavailability of 5 new 400 mg tablet fo...

Status

Completed

Location

Multiple Locations

Start Date

2009-05

Trial ID

NCT02182414

Treatments Being Tested

BI 207127 NA (TF-I)BI 207127 NA (TF-II)BI 207127 NA delayed release BI 207127 NA extended release (10% HPMC)BI 207127 NA extended release (15% PEO)BI 207127 NA extended release (20% HPMC)

Previous Next